Product
REGN10933 + REGN10987
Aliases
Casirivimab, Imdevimab, REGEN-COV™, REGN10933+REGN10987 combination therapy, REGN-COV2 (1 other aliases)
Name
Casirivimab
INN Name
Casirivimab
FDA Approved
Yes
3 clinical trials
1 organization
2 indications
1 document
Indication
Healthy ParticipantsIndication
COVID-19Clinical trial
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Hospitalized Patients With COVID-19Status: Completed, Estimated PCD: 2021-05-07
Clinical trial
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19Status: Terminated, Estimated PCD: 2022-01-21
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2Status: Completed, Estimated PCD: 2021-10-04
Document
DailyMed Label: CasirivimabOrganization
Regeneron Pharmaceuticals, Inc.